drugset / Trial / NCT01462786

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

NCT01462786

Phase 1 Completed 5 enrolled Kythera Biopharmaceuticals
RandomizedCrossoverOpen-labelTreatment

Summary

The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to compare the pharmacokinetic profile of ATX-101 administered into subcutaneous fat in the submental area and abdomen.

Timeline

Start
2011-10
Primary completion
2011-11
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ATX-101 Peptide 2 unknown Subcutaneous

Indications

No indication recorded.